Superworth

GENELUX EPS GNLX

Diluted earnings per share by quarter and over the last twelve months, from 2022.

Last 12 months, to Jun 30, 2026
−$0.86
Latest quarter, Q2 FY26
−$0.21
Fiscal year 2025
−$0.86

GENELUX's earnings per share was −$0.86 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.21.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.86n/a
FY2024−$0.96n/a
FY2023−$1.21n/a
FY2022$0.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.21n/a−$0.86
Q1 FY26−$0.20n/a−$0.85
Q4 FY25−$0.24n/a−$0.86
Q3 FY25−$0.21n/a−$0.88
Q2 FY25−$0.20n/a−$0.86
Q1 FY25−$0.21n/a−$0.88
Q4 FY24−$0.26n/a−$0.96
Q3 FY24−$0.19n/a−$0.95
Q2 FY24−$0.22n/a−$0.96
Q1 FY24−$0.29n/a−$0.97
Q4 FY23−$0.25n/a−$1.21
Q3 FY23−$0.20−141%−$1.34

Against its peers

Companies in Drug Manufacturers - General nearest GENELUX's size, closest first, today.

CompanyEPS, 12 monthsGrowth
GNLXGENELUX−$0.86
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on GENELUX

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.